[Renee]

NKGN delisted from the Nasdaq to the OTC

https://otce.finra.org/otce/dailyList?viewType=Additions

[glenn1919]

NKGN................................................https://stockcharts.com/h-sc/ui?s=NKGN&p=W&b=5&g=0&id=p86431144783











thx

[tw0122]

https://archive.fast-edgar.com/20250214/AA2PMQ2CZ22CKZK2222O2ZO26TB6ZZ223272/

[tw0122]

Back in at .52 as Meteors Capital took on 2.72m
Shares and is 7.84 owner 

[tw0122]

.53 cover shorty some more looking ok. Let's see if they try to hog Alzheimer's shares 

[tw0122]

.50 again Alzheimer's memory back 

[tw0122]

.46 cheapest Alzheimer's Pharma with FDA fast track out there ..the question is how long do Shorts or interested hedge fund parties hold it down ...20 million market cap is cheap for potential merger or cash to be made in the near future.
Hope is they bring down under .40 one more time to happily load more..

[tw0122]

Added .42-.43 average at .4360

[tw0122]

Back in for another flip at "@45

[tw0122]

Plenty of .51s available premarket for flipping at .58 and above 

[glenn1919]

NKGN...................................................lostintheshuffle......................................9

[Dantheoneman]

Ticker: NXU. 600 Billion Market Merge Approved. Moon 

[tw0122]

.51 ... This designation comes after promising safety and efficacy results from our Phase 1 trial, which shows early signs of clinical benefit in patients treated with troculeucel. Alzheimer's 

[tw0122]

.63 pop pop let's go .. SANTA ANA, Calif., Feb. 12, 2025 (GLOBE NEWSWIRE) --  NKGen Biotech, Inc. (Nasdaq: NKGN) (“NKGen” or the “Company”), a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous and allogeneic natural killer (“NK”) cell therapeutics, today announced that the U.S. Food and Drug Administration (“FDA”) has granted Fast Track designation for the investigation of troculeucel...

[tw0122]

.56 .. The Fast Track designation accelerates troculeucel’s path to U.S. FDA submission for the treatment of patients with moderate Alzheimer’s disease.

[tw0122]

.49 +40%Fast track FDA for Alzheimer's and float ok at 23m going for the magic $1

[Monksdream]

NKGN, 10Q due 12/20

[CaptPete1776]

Phase 2 trial data due this month and a decision on Dec 27 on who wins the funding bid to acquire the parent company in South Korea. 

[Monksdream]

NKGN, 10Q due per Seeking Alpha

[TrendTrade2016]

NKGN MINI BIO BEAST

[81vette]

Todays news is great,should see some uptrend as shorts get out and join the bulls team

[Monksdream]

NKGN anew 52/week low

[Volcano]

SANTA ANA, Calif., Sept. 12, 2024 (GLOBE NEWSWIRE) -- NKGen Biotech, Inc. (Nasdaq: NKGN) (“NKGen” or the “Company”), a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous and allogeneic natural killer (“NK”) cell therapeutics, today announced promising early interim data from the Phase 1 cohort and the dosing of the first Phase 2 patient in the Phase 1/2a clinical trial of troculeucel, NKGen’s cryopreserved autologous enhanced NK cell therapy for the treatment of moderate Alzheimer’s disease (“AD”).

The Phase 1 cohort is already demonstrating positive interim results. Early independent review of the data shows that after only three months treatment with a dose of 6 billion cells per treatment, the three patients in the Phase 1 cohort had no drug-related adverse reactions, and exploratory efficacy analyses showed that two of the three patients went from a moderate to a mild AD rating on the Clinical Dementia Rating-Sum of Boxes (“CDR-SB”) scale. These findings further support the company’s MX04 Phase 1 AD study, where the one moderate AD patient who received the highest dose in that study (4 billion cells) also went from a moderate to a mild rating on the CDR-SB. Additionally, six-month interim cognitive data from Phase 1 cohort patients receiving troculeucel is expected to be disclosed at an upcoming national Alzheimer’s conference in Q4 2024.

Building upon positive interim Phase 1 results of troculeucel in moderate Alzheimer’s patients, the Company is pleased to have dosed its first patient in the Phase 2 randomized, double-blind, placebo-controlled trial evaluating the efficacy of troculeucel compared to placebo in patients with moderate Alzheimer’s disease. Troculeucel will be evaluated for effectiveness and additional safety in a broader cohort of 30 patients with moderate Alzheimer’s disease, employing a randomized, double-blind setup (n=20 randomly assigned to the treatment arm and n=10 to placebo). The Phase 2 trial aims to provide a thorough understanding of both the potential benefits and limitations of troculeucel in treating Alzheimer’s disease, thereby validating its potential therapeutic efficacy. NKGen has now activated four clinical sites across North America and expects to increase enrollment in the coming months.

“We continue to make great progress with our troculeucel clinical program in AD,” said Paul Y. Song, MD, Chairman and CEO of NKGen. “In the Phase 1 cohort of the Phase 1/2a study, we can proudly announce two of our first three patients have been clinically upgraded from moderate to mild AD following only three months of treatment with troculeucel. Additionally, we have recently dosed the first patient in the Phase 2 cohort, which is a significant milestone, particularly since the dose used is cryopreserved and continuing at our highest dosing of 6 billion cells per treatment. With encouraging cognitive improvements and a favorable safety profile from the trial’s Phase 1 interim analysis, dosing our first patient in Phase 2 is a crucial step towards creating a much-needed treatment option for patients facing this challenging condition. We are particularly eager to explore the enhanced cognitive benefits that ongoing usage of the higher dosing may bring in our Phase 2 trial.”

[glenn1919]

NKGN...............................https://stockcharts.com/h-sc/ui?s=NKGN&p=W&b=5&g=0&id=p86431144783

[kindo]

I hope the old fart does it again here🤣🤣

[Monksdream]

NKGN under $2

[frans]

not the first time no news end may no news end june - now ??????

[kindo]

I was hoping for $2.00 which I thought was reasonable but apparently the results are not that good.

[frans]

was 0.36 =200% down not good at al - it was only an dreamer for 1000 % up

[kindo]

Doesn’t look good here!!!

[kindo]

Maybe they don’t have good results or maybe running out of money🤷‍♂️

[kindo]

Maybe they don’t have good results or maybe running out of money🤷‍♂️

[frans]

what is on here with NKGN ??????

[Monksdream]

NKGN under $2

[Volcano]

This is humongous news fir alzheimer

NKGen will present data on SNK01’s ability to reduce a-synuclein in Alzheimer’s patients, which is significant given that a-synuclein has been shown to correlate with worse cognitive function in Alzheimer’s disease. Presentation details are as follows:


Poster Title: Subjects treated with expanded non-genetically modified autologous Natural Killer cells (SNK01) show improved changes in CSF a-synuclein and in cognitive function

[Volcano]

www.nkgenbiotech.com

[glenn1919]

NKGN...............................https://stockcharts.com/h-sc/ui?s=NKGN&p=W&b=5&g=0&id=p86431144783

[georgie18]

NKGN...$1.25...Weekly Chart... https://schrts.co/FtMRTkVW ...setting up for a Symmetrical Triangle Breakout...Running in a $1.10/$1.36 Channel for the past 4 weeks...Looking for the Break/Hold of $1.36...🥳

[Monksdream]

Appears so not all high spec med techs make it

[frans]

is NKGN an dead stock ???? 1.17 X1.20

[Monksdream]

NKGN under $2

[frans]

NKGN no news from the last meeting from 6/10 to 6/13

[frans]

no news or when news ???

[frans]

what is going on here down down ????

[philaya]

Snk02 has extra benefits beyond cancer...
More values.

[frans]

the news is delayed to next week normal it was from 5/31 to june/3

[philaya]

Sold some...
Risky control.

[Volcano]

SANTA ANA, Calif., June 03, 2024 (GLOBE NEWSWIRE) -- NKGen Biotech, Inc. (Nasdaq: NKGN) (“NKGen” or the “Company”), a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous, allogeneic and CAR-NK natural killer (“NK”) cell therapeutics, today announced that Paul Y. Song, MD, Chairman and Chief Executive Officer of NKGen Biotech, will present details on their cryopreserved allogeneic NK cell therapy platform as well as updated Phase 1 data on its use in solid tumors without lymphodepletion at the 6th Annual Allogeneic Cell Therapies Summit to be held in Boston, MA, from June 10-12, 2024.

Presentation Details:

Title: Protecting Patients by Removing Need for Lymphodepletion to Better Preserve Immune Function

Conference Track: Clinical Track

Date and Time: Wednesday, June 12, 2024, 12:00 pm ET

Dr. Song’s presentation will detail the Company’s novel allogeneic blood-derived NK cell therapy (“SNK02”) commercial manufacturing and cryopreservation process, as well provide an update on their initial Phase 1 results using SNK02 to treat patients with advanced refractory solid tumors. Furthermore, Dr. Song will explore the potential benefits of eliminating pre-treatment lymphodepletion in patients undergoing SNK02 therapy, aiming to safeguard immune function and aid in recovery. Avoiding lymphodepletion before administering cancer treatment can provide many benefits including reduced toxicity, preservation of immune function, and potentially enhancing treatment efficacy. The presentation will also include a discussion on an unexpected discovery from the SNK02 Phase 1 trial, hinting at its possible applicability as a treatment for patients beyond cancer.

[Volcano]

Next week
100% pop coming

[frans]

where is the huge news ??? on Tuesday